ARCHIVES

Phase III Ramucirumab Trial Fails Primary Endpoint of PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

Minimally Invasive Radiation Said To Preserve Functions

April 24, 2009

Caplan: NEJM Should Go “The Extra Moral Mile”

January 9, 2009

Flat NIH Budget Threatens Future Of Research, Universities Say.

March 14, 2008

Vaccine and LDCT Pretreatment Can Help PDACs Become Vulnerable to Immunotherapy

June 27, 2014

New Drug Approval: Groups Urge FDA To Move Quickly On Herceptin Approval

September 18, 1998

NCI CTEP-Approved Trials For the Month of March

March 28, 2014